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INTRODUCTION
An understanding of the natural history of hepatitis
C virus (HCV) infection has improved in recent years.
However, immunological responses to hepatitis C
virus infection have not been fully studied. The disease
it causes is characterized by silent onset in most in-
fected individuals, a high rate of viral persistence and
the potential for development of ever-worsening chronic
liver disease, ranging from chronic hepatitis to cirrhosis
and occasionally to hepatocellular carcinoma. Such
progression, when it occurs, is also most commonly
a silent process that may take 20-40, and occasionally
even more, years to reach its end. Because of these
characteristics, it has been exceedingly difficult to
accurately assess the natural history (1, 2).
Hepatitis C virus infects an estimated 170 million
persons worldwide (1, 3). The prevalence of HCV
infections is 1 to 2%, although certain geographical
regions, age groups and ethnic groups have much
higher rates of infection (4). The natures of circu-
lating HCV particles and their association with im-
munoglobulins or lipoproteins as well as the charac-
terization of cell entry have all been subject to conflict-
ing reports (5).
Acute infection with HCV is characterized by a
disturbingly high propensity to progress to chronic
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hepatitis that, in a proportion of cases, may evolve
into cirrhosis and hepatocellular carcinoma (6, 7).
It is generally accepted that B-cells infected with
HCV clonally expand and produce autoantibodies.
When antigen-bound, these autoantibodies, along
with anti-HCV antibodies that target viral epitopes on
the surface of cells are known to circulate as immune
complex (IC). These IC may participate in the patho-
genesis of HCV (8). Immunoglobulins, which bind
other immunoglobulins or antibodies, add another
facet to the abnormal immune response of HCV in-
fected patients. In addition, when there is too much
autoreactive immunoglobulin, autoantibody response
may be dominant.
The present study was therefore designed to inves-
tigate the presence of these anti-immunoglobulin an-
tibodies, using as a target sheep immunoglobulins, in
HCV infected patients in an attempt to clarify some
immuno-pathogenetic aspects of B cell activation during
hepatitis C virus infection and to characterize distinct
changes in patterns of immunoglobulin levels in
hepatitis C infected patients.
PATIENTS AND METHODS
Anti-human IgA (G, M) antiserum (raised in rabbit),
human IgA (G, M), rabbit anti-human IgA (G, M)
conjugated to horseradish peroxidase (HRP), and
tetramethylbenzidine were purchased from Sigma
(Sigma-Aldrich Company Ltd, UK) andall other chemi-
cals were supplied from BDH (VWR International
Ltd, UK).
Patients
Informed patient consent was obtained in every case
and the use of blood or scientific studies was approved
by the local Ethical Committee. The study population
consisted of 45 normal adult individuals (group 1)
as a control group, 45 patients with recent-onset acute
HCV infection (group 2) and the same HCV-infected
individual serum samples pre-absorbed with sheep
immunoglobulins (group 3) were used for analysis
of immunoglobulin levels by enzyme-linked immuno-
sorbent assay (ELISA). Both group 1 and 2 were
matched for sex and age (median age, 39 years [range,
21 to 84 years]). Medical history, physical examina-
tion and routine laboratory investigations were com-
pletely normal in all subjects of group 1. They didn’t
use any medication prior to this study. Screening for
hepatitis B virus or human immunodeficiency virus
infection was negative in both patient and control
subjects. Sera were stored frozen at -80℃ until used.
At the initial consultation, all patients presented
were tested positive for HCV RNA by polymerase-
chain-reaction assay, had elevated serum alanine
amino-transferase levels and had been diagnosed
with acute HCV infection. If 1 or more of the follow-
ing criteria was met : known or suspected exposure
to HCV within the preceding 4 months, documented
with a known previous negative HCV test, or a serum
alanine amino-transferase level ofmore than 350 U/L,
with a documented normal level during theyear before
infection. Only 45 patients with HCV fulfilled these
conditions for admission to this study.
Human immunoglobulin measurement by ELISA
Coating antibody [anti-human IgA (IgG, IgM) an-
tiserum] was diluted 1 in 1000 in 1x coating buffer
(0.02 M Tris-HCl, 1.5 M NaCl pH 9.0) and 100 µl was
added to each of the wells of a microtiter plate (9, 10).
After overnight incubation at 4℃ the plate was washed
4 times with PBST20 (0.1% (w/v) [Tween 20 in 1x
PBS (phosphate buffered saline ; 0.25MNaCl, 0.0268
M KCl, 0.081 M Na2 HPO4 and 0.0146 M KH2PO4)].
Sites unoccupied by antibodywere blocked by addition
of 5% (w/v) Marvel (dried skimmedmilk) in PBS for
1 h at room temperature followed bywashing 6 times
with PBST20. The human serum samples were initially
diluted 1 in 2000 in 1x PBS, and 2 fold serial dilutions
subsequently performed on the plate. Diluted samples
were allowed to bind to the first antibody and the
plate was then washed 6 times in PBST20.
Rabbit anti-human IgA (IgG, IgM) conjugated to
HRP [second antibody] was diluted 1 in 1000 in 1x
PBS, 100 µl was added to each well of the microtiter
plate, incubated at room temperature for 1 h and then
washed 6 times in PBST20. The amount of bound
second antibody was determined by adding 200 µl of
the substrate solution [tetramethylbenzidine 6 mg/ml
in 0.1 M sodium acetate buffer pH 6.0] to each well.
After incubation in the dark at room temperature for
20 min, the reaction was stopped by adding 50 µl of
10% (w/v) H2SO4 to each well. The optical density
of each sample was read with an ELISA plate reader
with a 450-nm filter. A standard curve was constructed
by plotting absorbance against concentration for the
standard solutions and the concentration of immuno-
globulin (mg/ml) in the samples was determined.
Electrophoresis of immuno-precipitates on SDS
polyacrylamide gel
Human serum samples were immuno-precipitated
with anti-human IgG developed in rabbit in the pres-
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ence of sheep immunoglobulins. Serum samples
[25 µl] were diluted with sheep immunoglobulins
[475 µl] and, in addition, 75 µl of anti-IgG with 1x PBS
[425 µl]. After dilution, the antiserum and serum were
mixed to give a final volume of 1 ml and incubated
for 1 hour at room temperature. The precipitate was
removed by centrifugation at 13,000 rpm for 5 min
in micro centrifuge and then washed with 100 µl 1x
PBS. The antibody-antigen precipitate was dissolved
in 50 µl of 2x Laemmli sample buffer (0.125 M Tris-
HCl pH (6.8), 0.1% (w/v) SDS, 20% (w/v) glycerol,
0.005% (w/v) bromophenol blue) and then incubated
at 95℃ for 3 min (11) A fraction of this mixture [25 µl]
was electrophoresed overnight on a discontinuous
10% polyacrylamide gel containing 0.1% (w/v) SDS
at a constant voltage of 45 V at room temperature.
Following electrophoresis, proteins in gel were visu-
alized by staining with Coomassie blue staining (12).
Purification of HCV infected sera from the effect of
antibodies
Sheep immunoglobulins were isolated previously
from sheep serum by affinity chromatography using
the appropriate sepharose-bound antibody (Amer-
sham Pharmacia Biotech UK Ltd). The final puri-
fied antibody preparation contains only antigen-specific
active antibody plus a small amount of denatured an-
tibody resulting from elution procedure. Sheep im-
munoglobulins, 200 µl, at a concentration of 10 mg/l
in PBS, pH 7.2 weremixedwith 200µl of humanserum
samples from each of 45 HCV infected individuals
(diluted 1 in 10) to minimize further cross-reactivity
to human sera. The absorption was carried out for 1h
at 37℃, followed overnight at 4℃. The HCV infected
sera were clarified by centrifugation at 10000 x g for
15 min at 4℃ before testing (13). The absorption of
HCV infected sera with sheep immunoglobulins com-
pletely removed the positive reaction of these sera
(group 3), and then the concentration of immuno-
globulin present in each of these samples was deter-
mined by ELISA as described above.
Statistical analysis
After tabulating the data, the arithmetic mean for
each group was calculated. The variation or variability
in each groupwas represented by the standarddeviation
(SD). The means of the groupswere compared to see
if the differences were significant. Student’s t-test was
used to assess the significance of the difference be-
tween groups.
RESULTS
It was necessary to confirm the possibility that HCV
infected sera bind and co-precipitate with sheep im-
munoglobulins using immuno-precipitation reaction.
Results (Figure 1) showed that sheep immunoglobulins
precipitated more antibodies in HCV infected sera
(lanes 4-6) than in normal sera (lanes 1-3). Visual ex-
amination of the intensities of heavy chain bands
showed that sheep immunoglobulins bind and co-
precipitate with the antibody-antigen complex that
reveals differences in band intensities.
Furthermore, ELISA measurements showed that
group 2 had a high level of serum immunoglobulin
compared to group 3. The absorption of HCV infected
sera with sheep immunoglobulins was carried out
to eliminate the positive reaction of these sera and
the dramatic increase determined by ELISA was
varied between different HCV infected samples.
It was found (Table 1) that normal individuals had
mean IgA, IgG and IgM levels of 2.67 mg/ml, 9.39
mg/ml and 1.77 mg/ml, respectively while HCV
infected patients had mean levels of 3.19 mg/ml,
10.76 mg/ml and 1.94 mg/ml. These represented
Figure 1. Immuno-precipitation and polyacrylamide gel elec-
trophoresis of human serum samples with anti-human IgG. Three
normal serum samples (lanes 1-3) and three HCV infected sera
(lanes 4-6) were immuno-precipitated with anti-IgG developed
in rabbit in the presence of sheep immunoglobulins. H indi-
cates positions of immunoglobulin heavy chains. The precipitates
washed, dissolved in Laemmli sample buffer and analyzed by 10%
SDS polyacrylamide gel electrophoresis.
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significant increases in immunoglobulin levels in
the sera of HCV infected patients compared to normal
individuals (p＜0.0001, p＜0.00004 and p＜0.0004).
However, the mean levels of immunoglobulins A,
G and M in HCV infected sera (Figures 2, 3 & 4)
determined after purification from anti-sheep immu-
noglobulins, was 2.73 mg/ml, 9.55 mg/ml and 1.79
mg/ml, therefore, there were no significant differ-
ences in the sera of HCV infected patients compared
to normal individuals (p＜0.42, p＜0.36 and p＜0.44).
Our results in this study did not address any statistical
significant differences in sex variation (data not shown).
DISCUSSION
There is compelling evidence that HCV can infect
immune cells, such as macrophages, B cells and T
cells. It has been previously reported that HCV core,
the first protein expressed during the early phase of
viral infection, contains the immuno-modulatory func-
tion of suppressing host immune responses (8, 14).
This altered function of immune cells caused by HCV
infection may explain the ineffective immune response
to HCV. Despite this abundance of reports, most re-
searchers consider that whether the role of immu-
nological factors is primarily pathogenetic, co-causative,
secondary or simply chronologically associated to
pathogenetic events has not been definitively an-
swered (15). This problem has directed research to-
wards other possible immunological factors likely
to be present in HCV infected patients, in the attempt
to elucidate further the complex immunopathoge-
netic interactions of the disease : our finding of anti-
immunoglobulin antibody inHCV infected sera, lead-
ing to inaccuracies in immunoglobulin estimation by
immunoassay, represents a move in this direction.
In order to overcome this problem of interfering due
to the effect of anti-sheep immunoglobulin antibodies
on ELISA, the HCV infected human sera were pre-
treated with sheep immunoglobulins to eliminate cross-
reaction of other irrelevant antibodies found in HCV
infected sera and exclude false positive values, thereby
preventing unnecessary evaluation and treatment.
ELISA measurements showed that group 2 had a
Table 1. Statistical analysis of IgA, IgG and IgM measured by ELISA.
Study Group Case
Serum IgA
Level (mg/ml)
Serum IgG
Level (mg/ml)
Serum IgM
Level (mg/ml)
1 (n=45) Normal 2.67±0.37 9.39±0.83 1.77±0.14
2 (n=45) HCV infected 3.19±0.46＊ 10.76±0.65＋ 1.94±0.15#
3 (n=45)
HCV infected
(Purified)
2.73±0.40＊＊ 9.55±0.72＋＋ 1.79±0.13##
Values are MEAN±SD : ＊p＜0.0001, ＊＊p＜0.42 ; ＋p＜0.00004, ＋＋p＜0.36 ;
#p＜0.0004, ##p＜0.44 compared with normal individuals.
Figure 2. Serum IgA levels in groups of HCV infected and
unaffected control. Comparison of average serum IgA (mean±SD).
Figure 3. Serum IgG levels in groups of HCV infected and
unaffected control. Comparison of average serumIgG(mean±SD).
Figure 4. Serum IgM levels in groups of HCV infected and
unaffected control. Comparison of average serumIgM(mean±SD).
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higher level of serum IgA, IgG and IgM compared
to group 3. The dramatic increase determined by
ELISA was varied between different HCV infected
samples, hence this proves that it is not reliable to
use the human HCV infected sera directly without
pre-absorption. Thus, this sort of interaction led to
over-estimation of immunoglobulin levels in HCV
infected sera, which in turn produces unreliable results.
The concept is that different antibodies recognize
different epitopes together with the fact that the an-
tibody molecules are dimeric means that anti-sheep
immunoglobulin antibodies found in HCV infected
sera is able to formacross-linkedstructurewhenmixed
with antiserum.Hence, an antibody in antiserumbinds
to antibodies in HCV infected sera is not indicative
that the bound antibody is the antigen. Thus, it appears
that there was interactions arise during the analysis
of immunoglobulins.
Anti-sheep immunoglobulins antibodies found in
HCV infected sera greatly overestimate serum im-
munoglobulin concentration measurements in HCV
infected patients, regardless of the source of antibody
used. The possibility of interference with the antigen-
detection immunoassay for HCV infected patients by
anti-sera developed in sheep or goat was previously
investigated and concluded that antigen detection
ELISA for captures and detection might misdiagnose
HCV infected serum immunoglobulin concentration
(results not shown). Results indicate that this bias
will be avoided if reagents for capture and detection
are derived from different species such as rabbit.
This is in agreement with previous reports (16-18).
A mechanism that may account for this study is that
the presence of these anti-sheep immunoglobulins
antibodies in HCV infected patients may reflect the
increase production of autoantibodies and then, lead to
humoral immune abnormalities. This is best explained
by suggesting that there is an interaction producing
spurious immuno-precipitation as well as a circulating
immunoglobulin which is capable of binding other
autologous immunoglobulins may well interact with
other immune factors, thus participating in vivo in the
complex immunopathological events which occur in
HCV infected sera. Moreover, this study indicates the
risk factor of antibodies reacting with human immu-
noglobulins in sera fromHCV infected patients which
may play a major pathogenetic role by the generation
of autoantibodies.
Finally, the presence of circulating immune complex
may help to explain the immunological abnormalities
and extra-hepatic disorders observed inHCV infection,
thereby providing an opportunity for early intervention
that may be used for predicting disease in at-risk
populations. Furthermore, the presence of circulating
immune complex in serum during the early phase of
infection may contribute to the persistence of HCV
and its many immunopathological effects in the infected
host. The findings in this study may provide some
new insights into antibody response to HCV.
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